Multivalent Immunoglobulin Assemblies via DDD-AD Tethering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing bispecific antibodies face challenges such as high manufacturing costs, low expression yields, instability in serum, and heterogeneity, leading to impaired binding affinity and stability issues, making them unsuitable for commercial development and in vivo applications.
Innovation Solution
The development of stably tethered structures using specific interactions between dimerization and docking domains (DDD) and anchoring domains (AD) derived from cAMP-dependent protein kinase regulatory subunits and A-kinase anchoring proteins, allowing for site-directed covalent or non-covalent association of components, which are then stabilized with disulfide bridges or other crosslinking methods to enhance stability and binding affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If recombinant engineering methods are used to produce bispecific antibodies, then binding specificity is improved, but manufacturing cost increases and expression yield decreases
Solution Approach 1:
The patent segments the antibody structure into separate Fab fragments and Fc portions, which are produced independently through recombinant engineering and then assembled. This segmentation allows for optimized expression of each component separately, improving overall yield while maintaining the bispecific binding capability through controlled reassembly of the fragments.
2Strength
If chemical cross-linking methods are used to produce multivalent antibodies, then binding affinity is improved, but product heterogeneity increases and manufacturing cost increases
Solution Approach 1:
The patent introduces a controlled intermediary assembly process where Fab fragments and Fc portions are joined through specific protein-protein interactions or controlled cross-linking. This intermediary step ensures defined stoichiometry and structure, reducing product heterogeneity while maintaining high binding affinity through proper spatial arrangement of binding sites.
3Adaptability or versatility
If bispecific antibodies are produced with multiple binding sites, then functional versatility is improved, but stability in serum decreases and aggregation increases
Solution Approach 1:
The patent performs preliminary assembly and stabilization of the antibody structure through controlled association of Fab and Fc components before exposure to serum conditions. This preliminary action ensures proper folding and stable quaternary structure formation, preventing aggregation and enhancing serum stability while maintaining the multivalent functional versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of multivalent structures with defined composition, high yields, and improved stability, allowing for effective in vivo applications and enhanced binding affinity, overcoming the limitations of existing methods.
Implementation Method 1
specific interactions between two distinct peptide sequences, one termed dimerization and docking domain (DDD) and the other anchoring domain (AD)
Implementation Method 2
The association of the two components can be further stabilized by the formation of disulfide bridges between cysteine residues contained in the DDD and AD sequences
Data Source
AI summary
The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and/or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and/or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and/or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and/or diagnostic agents.